Hangzhou Tigermed Consulting Co., Ltd Dividend Information
Hangzhou Tigermed Consulting Co., Ltd has an annual dividend of 0.7408 per share, with a yield of 0.00%. The dividend is paid annually and the last ex-dividend date was Jun 17, 2025.
Dividend Yield
Annual Dividend
Ex-Dividend Date
0.00%
$0.7408
Jun 17, 2025
Payout Frequency
Payout Ratio
Annually
0.00%
Dividend History
Ex-Dividend Date
Cash Amount
Record Date
Pay Date
Jun 17, 2025
$0.30
Jun 16, 2025
Jun 17, 2025
Jul 12, 2024
$0.568
Jul 11, 2024
Jul 12, 2024
Jul 7, 2023
$0.55
Jul 6, 2023
Jul 7, 2023
May 31, 2022
$0.50
May 30, 2022
May 31, 2022
Jun 1, 2021
$0.30
May 31, 2021
Jun 1, 2021
May 22, 2020
$0.278
May 21, 2020
May 22, 2020
Dividend Charts
HNGZY Dividends
HNGZY Dividend Growth (YoY)
Follow-Up Questions
What is Hangzhou Tigermed Consulting Co., Ltd's current dividend paid and annual dividend?
The current dividend paid by Hangzhou Tigermed Consulting Co., Ltd is $0.30. The annual dividend for Hangzhou Tigermed Consulting Co., Ltd is $0.7408
What is Hangzhou Tigermed Consulting Co., Ltd's dividend payout ratio?
The dividend payout ratio for Hangzhou Tigermed Consulting Co., Ltd is 0.00%
What is the ex-dividend date for HNGZY?
The ex-dividend date for Hangzhou Tigermed Consulting Co., Ltd is Jun 17, 2025.
How often does Hangzhou Tigermed Consulting Co., Ltd pay dividends?
Quarterly. The last time Hangzhou Tigermed Consulting Co., Ltd paid dividend was on Jun 17, 2025
Key Stats
Prev.Close
$4
Open
$4.28
Day's Range
$4 - $4.28
52 week range
$4 - $4.2
Volume
612
Avg.Volume
0
Dividend yield
--
EPS (TTM)
0.15
Market Cap
$492.4M
What is HANGZHOU TIGERMED CONSULTING CO?
Hangzhou Tigermed Consulting Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Hangzhou, Zhejiang and currently employs 10,185 full-time employees. The company went IPO on 2012-08-17. Hangzhou Tigermed Consulting Co Ltd is a China-based holding company engaged in providing clinical trial services for research and development of new drugs. The firm operates two segments. The Clinical Trial Solutions segment provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies and thus help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical-Related and Laboratory Services segment is involved in provision of analytical services, such as data management and statistical analysis; logistics and execution support services, such as clinical trial site management; administrative assistance, such as patient recruitment; as well as consulting services. This segment also provides laboratory services for preclinical and clinical development stages through its subsidiary. The firm conducts its businesses in the domestic and overseas markets.